India, Nov. 19 -- Thursday, Abbott Laboratories (ABT) announced the initiation of its VOYAGER CE clinical trial to evaluate the safety and efficacy of its investigational Encantor software-guided, balloon-expandable transcatheter aortic valve implantation (TAVI) system for patients with symptomatic severe aortic stenosis.

The prospective, single-arm, pre-market study will enroll up to 300 patients across Europe and Australia. The first patient was enrolled at Macquarie University in Sydney, Australia, under the leadership of Stephen Worthley, M.B.B.S., Ph.D. The study is intended to support regulatory approval in Europe and Australia.

Aortic stenosis occurs when calcium buildup causes the aortic valve to narrow, restricting blood flow fro...